Once-a-day AVINZA® improves sleep quality measurements (polysomnographic and subjective) in patients treated for chronic moderate to severe Osteoarthritis (OA) pain

The ACTION study: A randomized, open-label, multicenter trial comparing once-a-day extended-release morphine sulfate capsules (AVINZA®) to twice-a-day controlled-release oxycodone hydrochloride tablets (OxyContin®) for the treatment of chronic, moderate to severe low back pain

“…Improved sleep in the A-MQD group confirms and extends the sleep findings reported by Caldwell et al 10 A recently reported polysomnography study confirmed these subjective sleep findings and provided objective measurements of the effects of A-MQD on various sleep parameters, including decreased latency to persistent sleep, number of night awakenings, and total wake time. 23 This study also demonstrated increased sleep efficiency, total sleep time, and Stage 2 sleep duration, with no significant decrease in REM duration from baseline.…”

A Study of AVINZA® (Morphine Sulfate Extended‐Release Capsules) for Chronic Moderate‐to‐Severe Noncancer Pain Conducted Under Real‐World Treatment Conditions—The ACCPT Study

“…For patients taking AVINZA for three months, significant improvements from baseline were also noted on Composite Sleep Scores and other measures of sleep evaluated. These results are consistent with the findings of a polysomnography study of AVINZA in patients with pain due to osteoarthritis, which showed that it decreased the latency to persistent sleep, number of night awakenings, and total wake time, and increased sleep efficiency, total sleep time, and Stage 2 sleep duration, with no significant decrease in REM duration from baseline 27 …”

“…After the initial period of titration, the median AVINZA daily dose stabilized at 60 mg for up to three months on study. This relatively low and stable morphine dose over time is consistent with other studies and is likely due to reliable around‐the‐clock pain relief achieved, with once‐daily AVINZA leading to few episodes of breakthrough pain 26,27 …”

“…In a large randomized study conducted in patients with chronic moderate‐to‐severe low back pain, once‐daily AVINZA was shown to result in around‐the‐clock pain relief and led to better pain scores, better sleep, and lower use of rescue medications compared to twice‐daily extended‐release oxycodone (OxyContin, Purdue Pharma LP, Stamford, CT, USA), and these results were achieved with a lower daily morphine‐equivalent dose 26 . A single‐blinded polysomnography study conducted in patients with moderate‐to‐severe osteoarthritis pain showed that AVINZA resulted in decreased latency to persistent sleep, number of night awakenings, and total wake time, and increased sleep efficiency, total sleep time, and Stage 2 sleep duration, with no significant decrease in Rapid Eye Movement duration from baseline 27 …”